CB —The Xience V (Abbott) stent consistently had better outcomes regarding target vessel revascularization, target lesion revascularization, MI and stent thrombosis compared to Taxus Liberté (Boston Scientific) at two years, based on the single-center, all-comer COMPARE trial, presented as a late-breaking clinical trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference Sept. 23. Lead author Peter Smits, MD, told Cardiovascular Business News that both the first- and second-generation Taxus stents are “inferior” to Xience.
